Imperial College London
Portrait Picture

Professor Reiko J. Tanaka

Faculty of Engineering, Department of Bioengineering

Professor of Computational Systems Biology & Medicine
 
 
 
//

Contact

 

+44 (0)20 7594 6374r.tanaka Website

 
 
//

Location

 

RSM 3.10Royal School of MinesSouth Kensington Campus

//

Summary

 

Publications

Citation

BibTex format

@article{McAleer:2019:10.1111/bjd.17088,
author = {McAleer, MA and Jakasa, I and Hurault, G and Sarvari, P and McLean, WHI and Tanaka, RJ and Kezic, S and Irvine, AD},
doi = {10.1111/bjd.17088},
journal = {British Journal of Dermatology},
pages = {586--596},
title = {Systemic and stratum corneum biomarkers of severity in infant AD include markers of innate and Th-related immunity and angiogenesis},
url = {http://dx.doi.org/10.1111/bjd.17088},
volume = {180},
year = {2019}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BACKGROUND: Biomarkers of atopic dermatitis (AD) are largely lacking, especially in infant AD. Those that have been examined to date have focused mostly on serum cytokines with few on non-invasive biomarkers in the skin. OBJECTIVES: We aimed to explore biomarkers obtainable from non-invasive sampling of infant skin. We compared these to plasma biomarkers and structural and functional measures of the skin barrier. METHODS: We recruited 100 infants at first presentation with AD, who were treatment naïve to topical or systemic anti-inflammatory therapies and 20 healthy children. We sampled clinically unaffected skin by tape stripping the stratum corneum (SC). Multiple cytokines and chemokines and natural moisturizing factors (NMF) were measured in the SC and plasma. We recorded disease severity and skin barrier function. RESULTS: 19 SC and 12 plasma biomarkers showed significant difference between healthy and AD skin. Some biomarkers were common to both the SC and plasma, and others were compartment-specific. Identified biomarkers of AD severity included Th2 skewed markers (IL-13, CCL17, CCL22, IL-5), markers of innate activation (IL-18, Il-1α, IL1β, CXCL8), angiogenesis (Flt-1, VEGF) and others (sICAM-1, vCAM-1, IL-16, IL-17A). CONCLUSIONS: We identified clinically relevant biomarkers of AD, including novel markers, easily sampled and typed in infants. These markers may provide objective assessment of disease severity and suggest new therapeutic targets, or response measurement targets for AD. Future studies will be required to determine if these biomarkers, seen in very early AD, can predict disease outcomes or comorbidities.
AU  - McAleer,MA
AU  - Jakasa,I
AU  - Hurault,G
AU  - Sarvari,P
AU  - McLean,WHI
AU  - Tanaka,RJ
AU  - Kezic,S
AU  - Irvine,AD
DO  - 10.1111/bjd.17088
EP  - 596
PY  - 2019///
SN  - 1365-2133
SP  - 586
TI  - Systemic and stratum corneum biomarkers of severity in infant AD include markers of innate and Th-related immunity and angiogenesis
T2  - British Journal of Dermatology
UR  - http://dx.doi.org/10.1111/bjd.17088
UR  - https://www.ncbi.nlm.nih.gov/pubmed/30132823
UR  - http://hdl.handle.net/10044/1/62001
VL  - 180
ER  -
Download